Glaukos Corporation $GKOS Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its position in shares of Glaukos Corporation (NYSE:GKOS) by 6.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 392,542 shares of the medical instruments supplier’s stock after purchasing an additional 24,284 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.69% of Glaukos worth $40,546,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Park Place Capital Corp raised its stake in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares during the period. AlphaQuest LLC grew its stake in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 633 shares in the last quarter. Bayforest Capital Ltd purchased a new stake in shares of Glaukos in the first quarter valued at approximately $141,000. Revisor Wealth Management LLC acquired a new stake in shares of Glaukos in the 2nd quarter worth $204,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Glaukos during the first quarter worth about $207,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

GKOS has been the topic of several recent analyst reports. UBS Group reaffirmed a “buy” rating and issued a $140.00 price target on shares of Glaukos in a research note on Monday. JPMorgan Chase & Co. lifted their target price on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, October 30th. BTIG Research increased their price objective on shares of Glaukos from $104.00 to $116.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Stifel Nicolaus set a $115.00 target price on Glaukos in a research report on Monday, October 27th. Finally, Mizuho set a $130.00 price objective on shares of Glaukos in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Glaukos has a consensus rating of “Moderate Buy” and an average price target of $119.08.

Glaukos Stock Up 3.2%

Glaukos stock opened at $92.76 on Thursday. The stock’s 50 day moving average price is $84.15 and its 200 day moving average price is $91.25. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company has a market cap of $5.33 billion, a PE ratio of -60.23 and a beta of 0.81. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The firm had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the previous year, the firm earned ($0.28) earnings per share. The firm’s revenue was up 38.1% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.